.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Teva
Baxter
Chinese Patent Office
Dow
Chubb
QuintilesIMS
Covington
Mallinckrodt
Farmers Insurance

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Method of treating androgenic alopecia with 5-.alpha.reductase inhibitors
Abstract:The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.
Inventor(s): Gormley; Glenn J. (Westfield, NJ), Kaufman; Keith D. (Westfield, NJ), Stoner; Elizabeth (Westfield, NJ), Waldstreicher; Joanne (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Filing Date:Feb 14, 1996
Application Number:08/601,497
Claims:1. A method of treating female pattern baldness comprising orally ale person in need of such treatment the 5.alpha.-reductase 2 inhibitor 17.beta.(N-tert.-butylcarbamoyl)-4-aza-5.alpha.-androst 1-ene-3-one in a dosage amount from 0.01 to 3 mgs/day.

2. The method of claim 1 wherein the dosage amount is from about 0.05 to 1.0 mg/day.

3. The method of claim 1 wherein the dosage amount is about 0.05 mg/day.

4. The method of claim 1 wherein the dosage amount is about 0.2 mgs/day.

5. A method of arresting and reversing female pattern baldness comprising orally administering to a female person in need of such treatment the 5.alpha.-reductase 2 inhibitor 17.beta.-(N-tert.-butylcarbamoyl)-4-aza-5.alpha.-androst-1-ene-3-one in an amount from 0.01 to 3 mgs/day.

6. The method of claim 5 wherein the dosage amount is about 0.2 mg/day.

7. The method of claim 5 wherein the dosage amount is about 0.05 mg/day.

8. The method of claim 1 wherein the dosage amount is about 1.0 mg/day.

9. The method of claim 5 wherein the dosage amount is about 1.0 mg/day.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Federal Trade Commission
Queensland Health
Deloitte
Johnson and Johnson
Express Scripts
Covington
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot